Everyone is encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1 ...
BioXcel Therapeutics (BTAI) provided an update on the progress of its late-stage clinical programs for lead neuroscience asset BXCL501, as well ...
The Russian authorities are preparing to ease the criteria for determining citizens' eligibility for military service to ...
The Business Research Company's Igalmi (Dexmedetomidine) Sublingual film to Transform Acute Agitation & Aggression Treatment Market in 2025 LONDON, GREATER LONDON, UNITED KINGDOM, January 31, 2025 ...
The New South Wales public mental health system is buckling under pressure, as the state grapples with mass resignations by ...
Peptide antigen-associated IgG levels were significantly lower in drug-naïve patients with first episode psychosis compared to control individuals.
As per the Brain and Behavior Research Foundation, it combines two compounds called xanomeline and trospium chloride. This is ...
"Mr. Elder was subsequently seen by Dr. Boston, a psychiatrist, in July 2021, who did not detect psychotic symptoms. Still, he highlighted negative symptoms reported by Mr. Elder's mother, such as ...
This symptomatic overlap may make it difficult to distinguish patients presenting with a cocaine-induced psychosis from those patients experiencing an acute schizophrenic episode, or to determine ...
MIAMI LAKES, Fla.--(BUSINESS WIRE)--Segal Trials, a privately held clinical research network specializing in acute schizophrenia and other psychiatric disorders, has released enrollment ...
Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a trio of late-stage trials. The phase 3 program missed both primary ...
Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints ...